Newsfeeds Archive - Page 61 of 167

1 minute read

Richardson Electronics Q1 EPS $0.45 Beats $0.24 Estimate, Sales $67.60M Beat $62.40M Estimate

October 5, 4:15 PM

Richardson Electronics (NASDAQ:RELL) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.24 by 87.5 percent. This is a 125 percent increase over earnings of $0.20 per share from

RELL

1 minute read

Redbook: US Retail Sales Up 12.3% YoY For Week Ended Oct. 1

By Bill Haddad

October 4, 8:55 AM

-Dow Jones

SPY

1 minute read

News

Adeia Renews Long-Term Intellectual Property License With Foxtel

By Bill Haddad

October 4, 8:41 AM

Foxtel, Australia’s leading pay-TV platform, and Adeia Inc., the newly independent IP licensing business (NASDAQ:ADEA), today announced that Foxtel has signed a multi-year intellectual property (IP) license

ADEA

2 minute read

XORTX Announces $5M Public Offering

By Bill Haddad

October 4, 8:31 AM

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat

TSXV:XRTX

1 minute read

Inhibrx Says Based On FDA Discussions, There Is Potential To Pursue Accelerated Approval For INBRX-101

By Bill Haddad

October 4, 8:13 AM

SAN DIEGO, Oct. 4, 2022 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that, based on

INBX

2 minute read

Exelixis Expands Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb To Include Fixed-Dose Combination Of Nivolumab And Relatlimab In Combination With XL092 In Phase 1b STELLAR-002 Trial

By Bill Haddad

October 4, 8:01 AM

Agreement enables evaluation of XL092 in combination with an additional immune checkpoint inhibitor — ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (NASDAQ:EXEL) today announced the expansion of its June 2021

BMY

1 minute read

Abeona Therapeutics Announces Completion Of Patient Follow-Up In Pivotal Phase 3 VIITAL Study Ff EB-101

By Bill Haddad

October 4, 7:36 AM

Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced that the last patient has completed their 6-month follow-up visit in Abeona’s pivotal Phase 3 VIITAL™ study of its investigational autologous, engineered

ABEO

3 minute read

Better Therapeutics Highlights Publication Of BT-001 Trial In ADA Diabetes Care Journal

By Bill Haddad

October 4, 7:32 AM

)-- Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today

BTTX

2 minute read

Autolus Therapeutics Announces Collaboration With Bristol Myers Squibb For Use Of Autolus’ Safety Switch System

By Bill Haddad

October 4, 7:09 AM

- Bristol Myers Squibb to receive access to Autolus’ RQR8 safety switch for use in cell therapy programs - - Autolus to receive an upfront payment, with potential for near term option exercise fees and development

AUTL

2 minute read

General

Nutriband And Kindeva Highlight Abuse-Deterrent Characteristics For AVERSA

By Bill Haddad

October 4, 7:07 AM

Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) with Kindeva Drug Delivery have demonstrated enhanced abuse deterrence kinetics of the Company's patented lead product, Aversa™ Fentanyl, an abuse-deterrent fentanyl

NTRB